Strong demand, sustained cost optimisation and operational excellence drives EBITDA margin of 24.8 per cent
Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2020.
The overall business grew by 22 per cent Y-o-Y with strong growth across the three businesses; demand-led traction in core therapies as COVID-19 portfolio normalises.
“I am pleased to see the strong execution across our markets and continued efforts on cost optimisation helping us drive revenue growth of 18 per cent Y-o-Y and a healthy EBITDA margin of 24.8%. In India, we have maintained market-beating performance across our core therapies as a contribution from the COVID-19 portfolio normalises in line with the reduction in infection cases. In the US, happy to see continued expansion in market share for Albuterol. Our businesses in South Africa and other international markets continued the momentum driven by strong demand in the base business and ramp-up in new launches. In line with our sustainability road map, we commissioned a 30 MW solar plant in Maharashtra which contribute significantly towards our objective of carbon neutral by 2025,” said Umang Vohra, MD and Global CEO, Cipla.
